These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8089066)

  • 1. Extended-spectrum beta-lactamase in Proteus mirabilis.
    Mariotte S; Nordmann P; Nicolas MH
    J Antimicrob Chemother; 1994 May; 33(5):925-35. PubMed ID: 8089066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmid-mediated cephalosporinase ACC-1 in clinical isolates of Proteus mirabilis and Escherichia coli.
    Girlich D; Karim A; Spicq C; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2000 Nov; 19(11):893-5. PubMed ID: 11152321
    [No Abstract]   [Full Text] [Related]  

  • 3. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
    Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
    J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of CTX-M-140, a Variant of CTX-M-14 Extended-Spectrum β-Lactamase with Decreased Cephalosporin Hydrolytic Activity, from Cephalosporin-Resistant Proteus mirabilis.
    Tian GB; Jiang YQ; Huang YM; Qin Y; Feng LQ; Zhang XF; Li HY; Zhong LL; Zeng KJ; Patil S; Xing Y; Huang X
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6121-6. PubMed ID: 27480855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of plasmid-encoded extended spectrum beta-lactamases produced by a clinical strain of Proteus mirabilis.
    Mahrouki S; Ben-Achour N; Chouchani C; Ben-Moussa M; Belhadj O
    Pathol Biol (Paris); 2009 May; 57(3):e55-9. PubMed ID: 18456422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interspecies spread of CTX-M-32 extended-spectrum beta-lactamase and the role of the insertion sequence IS1 in down-regulating bla CTX-M gene expression.
    Fernández A; Gil E; Cartelle M; Pérez A; Beceiro A; Mallo S; Tomás MM; Pérez-Llarena FJ; Villanueva R; Bou G
    J Antimicrob Chemother; 2007 May; 59(5):841-7. PubMed ID: 17332005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enzymatic resistance to beta lactam antibiotics within the genus Proteus and evaluation of Proteus mirabilis phenotypes and genotypes for resistance to third- and fourth-generation cephalosporins].
    Rodríguez C; Radice M; Perazzi B; Castro S; Juárez J; Santini P; Vay C; Famiglietti A; Gutkind G
    Enferm Infecc Microbiol Clin; 2005 Mar; 23(3):122-6. PubMed ID: 15757582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of extended-spectrum (beta)-lactamases and plasmid-mediated AmpC (beta)-lactamases among Korean isolates of Proteus mirabilis.
    Park YJ; Lee S; Kim YR; Oh EJ; Woo GJ; Lee K
    J Antimicrob Chemother; 2006 Jan; 57(1):156-8. PubMed ID: 16284101
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization of multiply resistant Proteus mirabilis isolates in Hungary.
    Konkoly Thege M; Nikolnikov S
    Acta Microbiol Hung; 1988; 35(4):423-8. PubMed ID: 3072825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3.
    Neuwirth C; Madec S; Siebor E; Pechinot A; Duez JM; Pruneaux M; Fouchereau-Peron M; Kazmierczak A; Labia R
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3591-4. PubMed ID: 11709345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo transferrable beta-lactam resistance due to a new plasmid-mediated oxyiminocephalosporinase from a clinical isolate of Proteus mirabilis.
    Watanabe Y; Yokota T; Higashi Y; Wakai Y; Mine Y
    Microbiol Immunol; 1991; 35(2):87-97. PubMed ID: 1886493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F2:A-:B- plasmid carrying the extended-spectrum β-lactamase bla(CTX-M-55/57) gene in Proteus mirabilis isolated from a primate.
    Dahmen S; Madec JY; Haenni M
    Int J Antimicrob Agents; 2013 Jun; 41(6):594-5. PubMed ID: 23507413
    [No Abstract]   [Full Text] [Related]  

  • 13. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
    Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.
    Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Typing of extended-spectrum beta-lactamase-producing Salmonella typhimurium strains isolated in a pediatric unit].
    Mhand RA; Soukri A; Amarouch H; Mdaghri NE; Benbachir M
    Sante; 1999; 9(6):341-4. PubMed ID: 10705312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular epidemiology of ceftazidime resistant Enterobacteriaceae from patients on a paediatric oncology ward.
    Hibbert-Rogers LC; Heritage J; Gascoyne-Binzi DM; Hawkey PM; Todd N; Lewis IJ; Bailey C
    J Antimicrob Chemother; 1995 Jul; 36(1):65-82. PubMed ID: 8537285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristic of fluoroquinolone resistant clinical isolates of K. pneumoniae, P. mirabilis and E. coli producing ESBL and AmpC beta-lactamases].
    Rzeczkowska M; Piekarska K; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(4):285-95. PubMed ID: 23484420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings.
    Ibrahimagić A; Bedenić B; Kamberović F; Uzunović S
    J Infect Chemother; 2015 May; 21(5):363-9. PubMed ID: 25638292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to beta-lactam antibiotics Proteus strains.
    Lachmajer-Lutoslawska M; Bobrowski M
    Acta Microbiol Pol A; 1975; 8(3):141-9. PubMed ID: 1103580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of TEM mutants in Proteus mirabilis.
    Bonnet R; De Champs C; Sirot D; Chanal C; Labia R; Sirot J
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2671-7. PubMed ID: 10543745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.